Case series of nebulizing r-tPA for COVID-19 induced acute respiratory distress syndrome.

Autor: Amini S; Department of Clinical Pharmacy, Faculty of Pharmacy Tehran University of Medical Science Tehran Iran.; Advanced Thoracic Research center Tehran University of Medical Science Tehran Iran., Labbani-Motlagh Z; Department of Clinical Pharmacy Tehran University of Medical Science Tehran Iran., Aliannejad R; Department of Clinical Pharmacy, Faculty of Pharmacy Tehran University of Medical Science Tehran Iran.; Advanced Thoracic Research center Tehran University of Medical Science Tehran Iran., Pourabbas SM; Department of Internal Medicine, Shari'ati Hospital Tehran University of Medical Science Tehran Iran., Vasei M; Cell-Based Therapies Research Center, Digestive Disease Research Institute, Shari'ati Hospital Tehran University of Medical Science Tehran Iran.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2022 Sep 05; Vol. 10 (9), pp. e6283. Date of Electronic Publication: 2022 Sep 05 (Print Publication: 2022).
DOI: 10.1002/ccr3.6283
Abstrakt: Fibrin deposition in the alveolar spaces during pulmonary involvement of COVID-19 impairs the O 2 /CO 2 exchange and leads to respiratory symptoms. In this report, Recombinant Tissue Plasminogen Activator (r-tPA) has been nebulized to 3 critically ill COVID-19 patients in order to resolve the deposited fibrin while avoiding the risk of bleeding. Based on these observations, nebulization of r-tPA may be a potential therapeutic approach and new area of research for future studies.
Competing Interests: The authors have no conflicts of interest to declare.
(© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje